Fate Therapeutics Inc. inked a multiyear, global collaboration worth up to $3 billion with Janssen Biotech Inc., which calls for the latter to contribute antigen binding domains for up to four tumor-associated targets. Read More
DUBLIN – Les Laboratoires Servier SAS has thrown its partner Symphogen A/S a lifeline by agreeing to a takeover deal in which the Danish firm will become Servier’s center of excellence for antibody development. Read More
Against a backdrop of nearly 15 global biopharma IPOs on deck on a day when all major U.S. market indices fell, shares of cancer drug developer Zentalis Pharmaceuticals Inc. (NASDAQ:ZNTL) shot up 29% to $23.20 on April 3 after an upsized initial filing to sell 9.2 million shares at a top-of-range $18 each. Read More
Having chalked up three marketed drugs after only nine years in existence, Venbio Partners LLC proved its appeal yet again by closing on about $394 million in a capital raise that included new and existing investors, with a broad range of institutional concerns in the mix. Read More
LONDON – A founding father of anti-angiogenesis therapy, Peter Carmeliet is turning his previous work on its head in new research which indicates that rather than destroying tumor vasculature, it should be piggy-backed as a means to recruit immune cells to a tumor. Read More
BioWorld looks at translational medicine, including: Microbiome changes precede tumor development in CRC; Converting catch and release to PARP traps; Smart bacterium senses environment; The dose makes the poison – timing, too; Minimal phenotyping gives minimal insights into MDD genetics; Hypoxia linked to common form of muscular dystrophy; Stopping tau in its tracks; Optogenetic plaque model traces neurodegeneration in AD; Once repulsive, always repulsive. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Axon, Denali, Neurocrine, Novan, Oryzon, Regeneron, Restorbio, Sanofi, Umecrine, Urogen, Voyager. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: American Cryostem, Aradigm, Brainstorm, Capricor, Celltrion, Emergent, Grifols, GSK, Icagen, Incyte, Innate, Innovax, Ligand, Neurocrine, Novartis, Regenerx, Ridgeback, Savara, Seneca, Siga, Sumitomo, Voltron. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Cytodyn, Gracell, I-Mab, Iveric, Novan, Revive. Read More
Triggered milestone payments disclosed by biopharma companies, including: Abbvie, AC Immune, Boehringer Ingelheim, Cytomx, Eli Lilly, Oxford. Read More